- Product revenues of $1.79 billion, an 18% increase compared to Q2 2020 -
- Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B -
- Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones across the pipeline expected in the next 6 to 9 months -
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.